Yahoo Finance

$51 Bn Orally Disintegrating Tablet Market Trends and Forecast to 2032

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By ...
Business Wire

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Nasdaq

Endo USA Expands Recall Of Clonazepam Orally Disintegrating Tablets

(RTTNews) - Endo USA, Inc., affiliated to generics and specialty branded pharmaceutical company Endo, Inc., has expanded its recall of Clonazepam Orally Disintegrating Tablets (C-IV), according to the ...
Nasdaq

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...
Business Wire

Edenbridge Pharmaceuticals Announces U.S. FDA Approval of DARTISLA ODT (Glycopyrrolate) Orally Disintegrating Tablets

- DARTISLA ODT is available as a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer PARSIPPANY, ...